Depreotide
Also known as: 111In‑DTPA‑Octreotide, 99mTc-depreotide, Depreotide, NeoSPECT, NeoTect, Octreoscan, P829, Pentetreotide, Technetium-99m depreotide
Source Depreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Depreotide is a radiolabeled octreotide derivative (111In‑DTPA‑D‑Phe1‑octreotide) used for diagnostic scintigraphy of somatostatin‑receptor positive tumors such as neuroendocrine tumors and carcinoids.
Mechanism of Action
high-affinity binding to somatostatin receptor subtype 2 (SSTR2) leading to accumulation of the Indium‑111 labeled peptide in receptor‑expressing tissues for scintigraphic imaging
Routes of Administration
Goals & Uses
- Carcinoid tumor stagingDiagnostic ImagingModerate
- Staging of lung cancerOncology ImagingModerate
- Detection of somatostatin receptor-positive tumorsOncology ImagingModerate
- Characterization of solitary pulmonary nodulesDiagnostic ImagingHigh
- Neuroendocrine tumor localizationDiagnostic ImagingHigh
Contraindications
- Hypersensitivity to depreotide or somatostatin analoguesAllergyHigh
- Known hypersensitivity to octreotide or indium‑111AllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- LactationReproductiveModerate
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
Adverse Effects
- Transient abdominal painGastrointestinalUncommon
- Radiation exposureRadiologicalCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Hypersensitivity/allergic reactionImmunologicalRare
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Radiation‑induced leukopeniaHematologicRare
Drug Interactions
- Octreotide / somatostatin analoguesModerate
- Somatostatin analog therapy (e.g., octreotide LAR)Low
- Other radiopharmaceuticalsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Diagnostic imaging of neuroendocrine tumorsDepreotide authorized in several EU member states
- United StatesApprovedApproved: Localization of somatostatin receptor positive tumorsmarketed as Octreoscan; Depreotide brand not used in US
- United KingdomWithdrawnwithdrawn from market in 2022
Approved by the FDA in 1999 for imaging of solitary pulmonary nodules. Also approved in Europe (NeoSPECT). Withdrawn from the US and EU markets around 2004–2005 for commercial/business reasons, not for safety concerns.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Depreotide?
Depreotide is a radiolabeled octreotide derivative (111In‑DTPA‑D‑Phe1‑octreotide) used for diagnostic scintigraphy of somatostatin‑receptor positive tumors such as neuroendocrine tumors and carcinoids.
What is Depreotide used for?
Depreotide is educationally associated with: Carcinoid tumor staging, Staging of lung cancer, Detection of somatostatin receptor-positive tumors, Characterization of solitary pulmonary nodules, Neuroendocrine tumor localization. Educational only — not medical advice.
How is Depreotide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Depreotide?
Reported adverse effects include: Transient abdominal pain, Radiation exposure, Injection site reactions, Headache, Hypersensitivity/allergic reaction, Flushing, Nausea, Radiation‑induced leukopenia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Depreotide?
Recorded contraindications: Hypersensitivity to depreotide or somatostatin analogues, Known hypersensitivity to octreotide or indium‑111, Pregnancy, Lactation, Breastfeeding. Consult a qualified clinician before use.